Latest Headlines

  1. LENZ Therapeutics Announces Submission Of New Drug Application To U.S. Food And Drug Administration For LNZ100 For The Treatment Of Presbyopia 8/12/2024

    LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the Company has submitted a New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for LNZ100 (an aceclidine-based ophthalmic solution) for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.

  2. 60 Degrees Pharma Provides University Of Kentucky With Right Of Reference To ARAKODA® NDA In Support Of SJ733 Phase IIb Study 8/12/2024

    60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it has granted the University of Kentucky a right of reference to the Company’s new drug application (“NDA”) for ARAKODA® (tafenoquine).

  3. Junshi Biosciences Announces Acceptance Of Supplemental New Drug Application For Toripalimab As First-Line Treatment Of Unresectable/Metastatic Melanoma 8/12/2024

    Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (NMPA) has accepted for review the supplemental new drug application (sNDA) for toripalimab (trade name: TUOYI®, product code: JS001) for the first-line treatment of unresectable or metastatic melanoma.

  4. Recursion And Exscientia Enter Definitive Agreement To Create A Global Technology-Enabled Drug Discovery Leader With End-To-End Capabilities 8/8/2024

    Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) today announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology-enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology-driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster.

  5. New Ligand-Guided Technique Enhances Drug Development 8/8/2024

    Researchers use chemical “helpers” called ligands to yield exceptionally precise chemical reactions.

  6. AI Can Speed Up Drug Development 8/8/2024

    Artificial intelligence (AI) can help identify molecules that could serve as new drugs for mental health disorders.

  7. DNA Topoisomerase Insights Hold Potential For Drug Discovery And Plant Protection 8/8/2024

    Insights into the function of DNA Topoisomerase VI (Topo VI) may provide a springboard for drug discovery and crop protection.

  8. Chugai In-Licenses Anti-TL1A Antibody RG6631 For The Intractable Diseases Ulcerative Colitis And Crohn's Disease 8/7/2024

    Chugai Pharmaceutical Co., Ltd. announced today that it has concluded a license agreement with F. Hoffmann-La Roche Ltd (hereafter “Roche”) [Head Office: Basel, Switzerland. Thomas Schinecker] for RG6631, the anti-TL1A antibody, currently in development for ulcerative colitis and Crohn’s disease.

  9. Bruker Announces Strategic Minority Investment In NovAliX 8/7/2024

    Bruker Corporation today announced a strategic investment in NovAliX, a preclinical Contract Research Organization (CRO) specializing in expert drug discovery services, headquartered in Strasbourg, France.

  10. AI Speeding Discovery Of New Drugs 8/6/2024

    The human body contains at least 20,000 different proteins, often called the “workhorses of the cell” because of their role in keeping cells healthy.